NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) had its target price hoisted by Ascendiant Capital Markets from $43.00 to $44.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, HC Wainwright boosted their price objective on NRx Pharmaceuticals from $2.00 to $19.00 and gave the stock a buy rating in a research report on Monday, August 5th.
Get Our Latest Research Report on NRx Pharmaceuticals
NRx Pharmaceuticals Trading Down 4.4 %
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.06. As a group, equities analysts forecast that NRx Pharmaceuticals will post -3.25 earnings per share for the current fiscal year.
Institutional Trading of NRx Pharmaceuticals
An institutional investor recently bought a new position in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned approximately 0.75% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- Compound Interest and Why It Matters When Investing
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Consumer Staples Stocks, Explained
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- The Role Economic Reports Play in a Successful Investment Strategy
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.